David Meyronet

6.6k total citations
115 papers, 2.6k citations indexed

About

David Meyronet is a scholar working on Genetics, Neurology and Molecular Biology. According to data from OpenAlex, David Meyronet has authored 115 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Genetics, 33 papers in Neurology and 26 papers in Molecular Biology. Recurrent topics in David Meyronet's work include Glioma Diagnosis and Treatment (52 papers), Meningioma and schwannoma management (21 papers) and Brain Metastases and Treatment (11 papers). David Meyronet is often cited by papers focused on Glioma Diagnosis and Treatment (52 papers), Meningioma and schwannoma management (21 papers) and Brain Metastases and Treatment (11 papers). David Meyronet collaborates with scholars based in France, United States and Switzerland. David Meyronet's co-authors include François Ducray, Jérôme Honnorat, Jacques Guyotat, Gabriele Bergers, Morag Park, Manish K. Aghi, Kan Lu, Shaun D. Fouse, Jeffrey P. Chang and Christine A. Parachoniak and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

David Meyronet

107 papers receiving 2.6k citations

Peers

Countries citing papers authored by David Meyronet

Since Specialization

Citations

This map shows the geographic impact of David Meyronet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Meyronet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Meyronet more than expected).

Fields of papers citing papers by David Meyronet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Meyronet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Meyronet. The network helps show where David Meyronet may publish in the future.

Co-authorship network of co-authors of David Meyronet

This figure shows the co-authorship network connecting the top 25 collaborators of David Meyronet. A scholar is included among the top collaborators of David Meyronet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Meyronet. David Meyronet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Feasibility and efficacy of MEMMAT-like regimen in heavily pretreated adult patients with recurrent malignant embryonal brain tumors: A series of 6 cases 2025 ·Neuro-Oncology Advances ·Aurélien Maureille, (unknown), David Meyronet, Cécile Faure, (unknown), Louis Larrouquère, Anne Pagnier, Marc Barritault, Alice Bonneville-Levard, Pierre Leblond	0
2	Demyelinating neuropathy as the initial presentation of familial E200K Creutzfeldt–Jakob disease in two patients 2025 ·Annals of Clinical and Translational Neurology ·Cécile Delorme, Antoine Pégat, (unknown), Jean‐Philippe Brandel, Emmanuel Roze, Karine Viala, (unknown), Stéphane Thobois, Anthony Fourier, E Bernard, Juliette Svahn, Chloé Laurencin, (unknown), Christophe Vandendries, Isabelle Quadrio, (unknown), David Meyronet, Thierry Maisonobe, (unknown), Danielle Seilhean	0
3	Predictors of Progression in a Series of 81 Adult Patients Surgically Managed for an Intracranial Hemangioblastoma: Implications for the Postoperative Follow-Up 2024 ·Cancers ·(unknown), (unknown), Jacques Guyotat, I. Pélissou-Guyotat, Timothée Jacquesson, (unknown), Romain Manet, (unknown), Tanguy Fenouil, Nathalie Streichenberger, Alexandre Vasiljevic, David Meyronet, Emmanuel Jouanneau, François Ducray, Chloé Dumot, Thiébaud Picart	2
4	Robust estimation of 5-ALA-induced PpIX contributions in multiple-wavelength excitation fluorescence spectroscopy to improve intraoperative glioma detection: application on clinical data 2024 ·SPIRE - Sciences Po Institutional REpository ·(unknown), Michaël Sdika, Jacques Guyotat, (unknown), David Meyronet, Thiébaud Picart, Bruno Montcel	0
5	Early Detection of Underlying Cavernomas in Patients with Spontaneous Acute Intracerebral Hematomas 2023 ·American Journal of Neuroradiology ·(unknown), Omer Eker, Tae‐Hee Cho, Roxana Améli, Moncef Berhouma, Matteo Cappucci, Laurent Derex, Laura Mechtouff, David Meyronet, Norbert Nighoghossian, Yves Berthezène, M. Hermier	0
6	RSL24D1 sustains steady-state ribosome biogenesis and pluripotency translational programs in embryonic stem cells 2023 ·Nature Communications ·Sébastien Durand, (unknown), (unknown), (unknown), Juliana Blin, (unknown), (unknown), Sylvie Martel, (unknown), Christophe Vanbelle, Annie Adrait, Yohann Couté, David Meyronet, Frédéric Catez, Jean‐Jacques Diaz, Fabrice Lavial, Emiliano P. Ricci, François Ducray, Mathieu Gabut	11
7	CTNI-33. TARGET TRIAL: A PHASE I/II OPEN-LABEL MULTICENTER STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFICACY OF AZD4547 IN PATIENTS WITH RELAPSED/REFRACTORY FGFR FUSION POSITIVE GLIOMA 2023 ·Neuro-Oncology ·Alberto Pïcca, Anna Luisa Di Stefano, Julien Savatovsky, François Ducray, Olivier Chinot, E. Cohen-Jonathan Moyal, Paule Augereau, Yohann Schmitt, (unknown), (unknown), Christine Fardeau, Karima Mokhtari, Franck Bielle, David Meyronet, Antonio Iavarone, Marc Sanson	2
8	Clinical and pathological impact of an optimal assessment of brain invasion for grade 2 meningioma diagnosis: lessons from a series of 291 cases 2022 ·Neurosurgical Review ·Thiébaud Picart, Chloé Dumot, Jacques Guyotat, Vladislav Pavlov, Nathalie Streichenberger, Alexandre Vasiljevic, Tanguy Fenouil, Anne Durand, Emmanuel Jouanneau, François Ducray, Timothée Jacquesson, Moncef Berhouma, David Meyronet	3
9	Characteristics and management of hydrocephalus in adult patients with cerebellar glioblastoma: lessons from a French nationwide series of 118 cases 2021 ·Neurosurgical Review ·Thiébaud Picart, Chloé Dumot, David Meyronet, Johan Pallud, Philippe Métellus, Sonia Zouaoui, François Ducray, I. Pélissou-Guyotat, Moncef Berhouma, Luc Bauchet, Jacques Guyotat, (unknown), (unknown)	6
10	Brain virtual histology with X-ray phase-contrast tomography Part II: 3D morphologies of amyloid-β plaques in Alzheimer’s disease models 2021 ·Biomedical Optics Express ·(unknown), (unknown), (unknown), (unknown), David Legland, Ignacio Arganda‐Carreras, (unknown), Françoise Peyrin, Hervé Boutin, Nicolas Rama, Thierry Baron, David Meyronet, Emmanuel Brun, (unknown), Marlène Wiart, Fabien Chauveau	9
11	Management, functional outcomes and survival in a French multicentric series of 118 adult patients with cerebellar glioblastoma 2021 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Thiébaud Picart, (unknown), David Meyronet, Johan Pallud, Chloé Dumot, Philippe Métellus, Sonia Zouaoui, Moncef Berhouma, François Ducray, Luc Bauchet, Jacques Guyotat	5
12	Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults 2021 ·Neuro-Oncology Advances ·Thiébaud Picart, Marc Barritault, Delphine Poncet, (unknown), Cristina Izquierdo, Émeline Tabouret, Dominique Figarella‐Branger, Ahmed Idbaïh, Franck Bielle, Véronique Bourg, Fanny Burel‐Vandenbos, Elizabeth Cohen‐Jonathan Moyal, (unknown), Jacques Guyotat, Jérôme Honnorat, Mathieu Gabut, David Meyronet, François Ducray	47
13	Characteristics of IDH-mutant gliomas with non-canonical IDH mutation 2020 ·Journal of Neuro-Oncology ·(unknown), (unknown), (unknown), Hugues Loiseau, (unknown), Aurore Siegfried, Romuald Seizeur, Guillaume Gauchotte, David Cappellen, Alain Carpentier, Dominique Figarella-Branger, Sandrine Eimer, David Meyronet, François Ducray	23
14	Machine learning-based prediction of glioma margin from 5-ALA induced PpIX fluorescence spectroscopy 2020 ·HAL (Le Centre pour la Communication Scientifique Directe) ·Pierre Leclerc, (unknown), (unknown), (unknown), Carole Frindel, Pierre‐François Brevet, David Meyronet, Jacques Guyotat, Bruno Montcel, David Rousseau	1
15	Spectral complexity of 5-ALA induced PpIX fluorescence in guided surgery: a clinical study towards the discrimination of healthy tissue and margin boundaries in high and low grade gliomas 2019 ·Biomedical Optics Express ·(unknown), (unknown), Mathieu Hébert, (unknown), David Meyronet, David Rousseau, Jacques Guyotat, Bruno Montcel	36
16	Liponeurocytoma of the Cerebellopontine Angle 2018 ·World Neurosurgery ·(unknown), (unknown), Timothée Jacquesson, David Meyronet, François Cotton, Emmanuel Jouanneau, Moncef Berhouma	4
17	Characteristics of gliomas in patients with somatic IDH mosaicism 2016 ·Acta Neuropathologica Communications ·Charlotte Bonnet, Laure Thomas, Dimitri Psimaras, Franck Bielle, Élodie Vauléon, Hugues Loiseau, Stéphanie Cartalat‐Carel, David Meyronet, Caroline Dehais, Jérôme Honnorat, Marc Sanson, François Ducray	26
18	CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling 2015 ·Cancer Research ·Aubin Moutal, Jérôme Honnorat, (unknown), (unknown), (unknown), (unknown), Chantal Watrin, Naura Chounlamountri, (unknown), Roger Besançon, (unknown), (unknown), Rajesh Khanna, François Ducray, David Meyronet, Nicole Thomasset	37
19	Influence of Pre-analytical Variables on VEGF Gene Expression and Circulating Protein Concentrations 2012 ·Biopreservation and Biobanking ·Mohsen Azimi–Nezhad, Daniel Lambert, Catherine Ottone, Corinne Perrin, (unknown), (unknown), Michèle Pfister, Christine Masson, Éric Tabone, Fay Betsou, David Meyronet, Marie‐Noëlle Ungeheuer, Sophie Visvikis‐Siest	14
20	Lymphome pulmonaire du MALT révélant un sida 2006 ·Revue des Maladies Respiratoires ·Alexis B. Cortot, (unknown), B. Issartel, David Meyronet, Bertrand Coiffier, J.-F. Cordier	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact